Company news

Atrium Therapeutics, Inc. news in 2026

Atrium Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome

October 27, 2026

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

October 20, 2026

Atrium Therapeutics to Participate in Upcoming Investor Conferences

September 2, 2026

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

August 13, 2026

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

July 14, 2026

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 23, 2026

Atrium Therapeutics Reports First Quarter 2026 Financial Results

May 14, 2026

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

April 23, 2026

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 20, 2026

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

February 27, 2026

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

February 27, 2026

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

February 26, 2026

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

February 23, 2026

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

February 18, 2026

Avidity Biosciences Announces Expected Record Date for Spin-Off

February 1, 2026

Decks in 2026